NPPA fixes ceiling price of Mannitol Injection
New Delhi: After considering the Wholesale Price Index (WPI) at 10.76607% for the year 2021 over 2020, the National Pharmaceutical Pricing Authority (NPPA) panel, has fixed the ceiling price for Mannitol Injection at 20% in 100ml packages in non-glass containers in a plastic bottle with euro head having special features manufactured by 3 different pharmaceuticals.
According to the new price notified by the drug price regulator, the ceiling price of Mannitol Injection 20% is 0.382 Rs per ml.
This came in line with the Wholesale Price Index (WPI) data provided by the Office of Economic Advisor, Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry whereby the annual change in WPI works out as 10.76607% during the calendar year 2021 over the corresponding period over 2020.
The three manufacturers of Mannitol Injection 20% are Otsuka Pharmaceutical, Denis Chem Lab, Rusoma Laboratories.
Mannitol is a diuretic that is used to reduce swelling and pressure inside the eye or around the brain. Mannitol is also used to help your body produce more urine. mannitol injection is used in people with kidney failure, to remove excess water and toxins from the body.
Mannitol is sometimes given so that your body will produce enough urine to be collected and tested. This helps your doctor determine if your kidneys are working properly.
In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 and paragraph 14 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 3938(E) dated 23.09.2021 and S.O. 5427(E) dated 28.12.2021, in so far as they relate to Mannitol Injection 20% in 100 ml pack for packages in non-glass container in plastic bottle with euro head having special features like (i) self-collapsibility and self-sealeability (ii) not having air-vent and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels mentioned in the Table A herein below, manufactured by the manufacturers specified in Table B for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, has revised the price based on Wholesale price index(WPI) of 2021 as specified in column (5) of the Table A herein below as separate ceiling price exclusive of goods and services tax applicable, if any, in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:
Sl.No | Medicines | Dosage form and Strength | Unit | Ceiling price(wef01.04.2022 with WPI @ 10.76607 % |
(1) | (2) | (3) | (4) | (5) |
1 | Mannitol | Injection 20% in 100ml pack for packages in a non-glass container in a plastic bottle with euro head having special features | Per ml | 0.382 |
The notification further added;
(a) The ceiling prices are applicable with effect from 01.04.2022 (ceiling prices are inclusive of Wholesale Price Index (WPI) @10.76607% for the year 2021 over 2020).
(b) The manufacturers of scheduled formulations, selling above said products/brand name of scheduled formulations at price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable if any.
(c) The manufacturers of above mentioned scheduled formulations have MRP lower than the ceiling price specified in column (5) in the above table (plus goods and services tax as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @10.76607% for the year 2021 over 2020 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.
To view the official notice, click the link below:
https://www.nppaindia.nic.in/wp-content/uploads/2022/03/1505E_Menni_Eng.pdf
